Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Stock Keeps “Outperform” Rating at Wedbush

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA)‘s stock had its “outperform” rating reaffirmed by Wedbush in a research note issued on Tuesday, Benzinga reports. They presently have a $40.00 target price on the stock. Wedbush’s price target suggests a potential upside of 96.37% from the company’s current price.

Other research analysts also recently issued research reports about the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research note on Monday, September 14th. Guggenheim raised their target price on Damora Therapeutics, Inc. Common Stock from $40.00 to $60.00 and gave the stock a “buy” rating in a research note on Friday. TD Cowen upgraded Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a research report on Monday, August 24th. HC Wainwright reiterated a “buy” rating and set a $45.00 price target on shares of Damora Therapeutics, Inc. Common Stock in a research report on Tuesday, July 21st. Finally, Jefferies Financial Group initiated coverage on Damora Therapeutics, Inc. Common Stock in a report on Monday, July 27th. They set a “buy” rating and a $50.00 price objective on the stock. Three research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $46.50.

Damora Therapeutics, Inc. Common Stock Stock Down 1.8%

Damora Therapeutics, Inc. Common Stock stock traded down $0.38 during midday trading on Tuesday, hitting $20.37. 86,755 shares of the stock were exchanged, compared to its average volume of 424,377. The company has a fifty day simple moving average of $28.18 and a two-hundred day simple moving average of $26.27. Damora Therapeutics, Inc. Common Stock has a 52 week low of $3.50 and a 52 week high of $38.33. The stock has a market capitalization of $1.26 billion, a PE ratio of -6.04 and a beta of 1.46.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.06. As a group, equities research analysts anticipate that Damora Therapeutics, Inc. Common Stock will post -2.06 EPS for the current fiscal year.

Insider Activity

In related news, CEO Jennifer Jarrett acquired 12,500 shares of the stock in a transaction dated Friday, September 25th. The stock was acquired at an average cost of $20.23 per share, with a total value of $252,875.00. Following the purchase, the chief executive officer directly owned 512,500 shares of the company’s stock, valued at approximately $10,367,875. This trade represents a 2.50% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Seven Fleet Capital Management LP purchased a new stake in Damora Therapeutics, Inc. Common Stock in the second quarter valued at approximately $7,398,000. Braidwell LP purchased a new position in Damora Therapeutics, Inc. Common Stock during the 2nd quarter worth approximately $42,146,000. Squarepoint Ops LLC purchased a new position in Damora Therapeutics, Inc. Common Stock during the 2nd quarter worth approximately $303,000. Finally, Arizona State Retirement System purchased a new position in Damora Therapeutics, Inc. Common Stock during the 2nd quarter worth approximately $260,000. 14.20% of the stock is currently owned by hedge funds and other institutional investors.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.